

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
00786/304003

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Vladimir P. Torchilin et al.FILING DATE
April 5, 1999

GROUP

(37 CFR 1.98(b))

J1017 U.S. PTO
10/081223
02/22/02

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AB	WO 96/00084	06/21/95	PCT				
	AC	WO 97/16232		PCT Search Report				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	AD	Banks et al., "Characterization of Cross-Reactive Anti-DNA Auto Antibodies in Murine Lupus", <u>Immunological Investigations</u> , 22(3), 229-248 (1993)
	AE	Ben-Yehuda et al., "Immune Senescence: Mechanisms and Clinical Implications", <u>Infectious Complications of Cancer</u>
	AF	Chatterjee et al., "Idiotypic antibody immunotherapy of cancer", <u>Cancer Immunol. Immunother.</u> , 38:75-82 (1994)
	AG	Chen et al., "A Comparative Autoradiographic Study Demonstrating Differential Intratumor Localization of Monoclonal"..., <u>Journal of Nuclear Medicine</u> , 31:1059-1066 (1990)
	AH	Cronstein et al., "The Adhesion Molecules of Inflammation", <u>Arthritis and Rheumatism</u> , 36:147-157 (1993)
	AI	Goding, James W., "Monoclonal Antibodies: Principles and Practice", <u>Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology</u> , Second Edition, Academic Press (1986)
	AJ	Iakoubov et al., "Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells", <u>Immunology Letters</u> , 47:147-149 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
00786/304003

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Vladimir P. Torchilin et al.FILING DATE
April 5, 1999

GROUP

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	BB	Jacob et al., "A monoclonal anti-double-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types", <u>Proc. Natl. Acad. Sci.</u> , 86:4669-4673 (1989)
	BC	Jain, Rakesh K., "Barriers to Drug Delivery in Solid Tumors", <u>Scientific American</u> , July 1994
	BD	Langdon et al., "Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked....", <u>B. J. Cancer</u> , 63:909-915 (1991)
	BE	Muller et al., <u>Methods in Enzymology</u> , 170:251-263 (1989)
	BF	Osband et al., "Problems in the Investigational Study and Clinical use of cancer immunotherapy", <u>Immunology Today</u> , 11:193-195 (1990)
	BG	O'Sullivan et al., "Long-Term Anti-CD4 Treatment of MRL/lpr Mice Ameliorates Immunopathology and Lymphoproliferation", <u>Clinical Immunology and Immunopathology</u> , 61:421-435 (1991)
	BH	Prabhakar et al., "Cell Surface Expression of the 70-kD Component of Ku, a DNA-binding Nuclear Autoantigen", <u>The Journal of Clinical Investigation Inc.</u> , 86:1301-1305 (1990)
	BI	Raz et al., "Cross-reactions of anti-DNA autoantibodies with cell surface proteins", <u>Eur. J. Immunol.</u> , 23:383-390 (1993)
	BJ	Rekvig, O.P., "Intrinsic Cell Membrane Antigens Recognized by Antichromatin Autoantibodies", <u>Scand. J. Immunol.</u> , 29:7-13 (1989)
	BK	Rekvig et al., "Properties of Antinuclear Antibodies that Cross-react with Plasma Membranes", <u>Scand. J. Immunol.</u> 9:325-332 (1979)
	BL	Rhodes et al., "Assembly of Nucleosomes and Chromatin <i>in Vitro</i> ", <u>Methods in Enzymology</u> , 170:575-585 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 00786/304003		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Vladimir P. Torchilin et al.			
				FILING DATE April 5, 1999		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	CB						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	CC	Ricotti et al., "Autoantibodies to purified nuclear proteins related to DNA metabolism during ageing and in SLE patients",					
	CD	Sakharova et al., "Ontogenetic Changes in Spectrum of Specificities of Brain Reactive Monoclonal Natural Antibodies", <u>Zh. Obshch. Biol.</u> , 47:625-630 (1986)					
	CE	Searles et al., Cross-reactivity of Antilymphocyte and Antinuclear Antibodies in Systemic Lupus Erythematosus", <u>Clinical Immunology and Immunopathology</u> 14:292-299 (1979)					
	CF	Stollar et al., <u>Int. Rev. Immunol.</u> , 5:1-24 (1989)					
	CG	Walker et al., "Accelerated Appearance of Neoplasms in Female NZB/NZW Mice Treated with", <u>Arthritis and Rheumatism</u> , 22:1338-1342 (1979)					
	CH	Walker et al., "Suppressed heterogeneous antinuclear antibody response in lymphoma-bearing NZB/NZW mice", <u>Clin. exp. Immunol.</u> , 24:210-217 (1976)					
	CI	Winter et al., "Antibodies Against Autologous Tumor Cell Proteins in Patients with Small-Cell Lung Cancer.....", <u>J. National Cancer Institute</u> , 85:2012-2018 (1993)					
	CJ						
	CK						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
00786/304003

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Vladimir P. Torchilin et al.FILING DATE
April 5, 1999

GROUP

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	DL							
	DM							
	DN							
	DO							
	DP							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	DQ	Ezell (J. NIH Res., 7:46-69), 1995
	DR	Splitler (Cancer Biotherapy, 10:1-3), 1995
	DS	Boon (Adv. Can. Res., 58:177-210), 1992

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.